GC
AMLX icon

Guggenheim Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Guggenheim Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355K Buy
25,513
+270
+1% +$3.8K ﹤0.01% 1321
2025
Q4 		$305K Buy
25,243
+344
+1% +$4.67K ﹤0.01% 1522
2025
Q3 		$338K Sell
24,899
-10,853
-30% -$102K ﹤0.01% 1349
2025
Q2 		$229K Sell
35,752
-2,044
-5% -$9.94K ﹤0.01% 1468
2025
Q1 		$134K Buy
37,796
+1,928
+5% +$6.86K ﹤0.01% 1583
2024
Q4 		$136K Buy
35,868
+20,470
+133% +$96.3K ﹤0.01% 1639
2024
Q3 		$49.9K Sell
15,398
-50
-0.3% -$112 ﹤0.01% 1848
2024
Q2 		$29.4K Sell
15,448
-890
-5% -$1.73K ﹤0.01% 1854
2024
Q1 		$46.4K Buy
16,338
+1,392
+9% +$18.2K ﹤0.01% 1862
2023
Q4 		$220K Buy
+14,946
New +$229K ﹤0.01% 1781

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Guggenheim Capital's AMLX Position: Q1 2026 in Review

Guggenheim Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 1.1% in Q1 2026, buying an estimated $3.8K and bringing the position to 25,513 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Guggenheim Capital first reported a position in AMLX in Q4 2023 and has held it in 10 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Guggenheim Capital held 25,513 shares of Amylyx Pharmaceuticals worth $355K as of Q1 2026.
  • Guggenheim Capital bought 270 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.8K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1321 holding.
  • Guggenheim Capital first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.